Zhengye Biotechnology (NASDAQ:ZYBT) Stock Price Up 3.1% – Here’s What Happened

Posted by George Bondi on Jun 11th, 2026

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT – Get Free Report)’s share price rose 3.1% on Tuesday . The company traded as high as $0.8910 and last traded at $0.8910. Approximately 72,710 shares traded hands during trading, an increase of 97% from the average daily volume of 36,849 shares. The stock had previously closed at $0.8640.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Zhengye Biotechnology from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, May 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Get Our Latest Report on ZYBT

Zhengye Biotechnology Stock Down 0.0%

The business’s fifty day moving average is $0.93 and its two-hundred day moving average is $1.13. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.14 and a quick ratio of 0.82.

Zhengye Biotechnology (NASDAQ:ZYBT – Get Free Report) last posted its earnings results on Tuesday, April 28th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $3.97 million for the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in shares of Zhengye Biotechnology during the second quarter valued at approximately $1,158,000. Invesco Ltd. purchased a new position in shares of Zhengye Biotechnology during the second quarter valued at approximately $220,000. XTX Topco Ltd boosted its position in shares of Zhengye Biotechnology by 71.4% during the fourth quarter. XTX Topco Ltd now owns 59,286 shares of the company’s stock valued at $68,000 after buying an additional 24,697 shares during the period. WINTON GROUP Ltd boosted its position in shares of Zhengye Biotechnology by 193.8% during the fourth quarter. WINTON GROUP Ltd now owns 63,297 shares of the company’s stock valued at $73,000 after buying an additional 41,750 shares during the period. Finally, Geode Capital Management LLC purchased a new position in shares of Zhengye Biotechnology during the second quarter valued at approximately $174,000.

Zhengye Biotechnology Company Profile

(Get Free Report)

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.